1.. Introduction {#s1}
================

To study mutations in the genomic sequences of cancerous tissues, we use the statistic introduced initially by Kolmogorov \[[@RSOS150143C1]\] and later developed by Arnold \[[@RSOS150143C2],[@RSOS150143C3]\] in defining a degree of randomness (stochasticity) for a given sequence of real numbers. The universality of the method has been revealed in measuring the degree of randomness of finite sequences in theory of dynamical systems and in number theory \[[@RSOS150143C2]\]. This approach has been applied to physical problems, i.e. in the study of non-Gaussianities in cosmic microwave background radiation \[[@RSOS150143C4]--[@RSOS150143C6]\] and of X-ray galaxy clusters \[[@RSOS150143C7]\]. This method was instrumental in detecting the thermal trust effect (Yarkovsky--Rubincam effect) for the first time in the properties of satellites probing General Relativity \[[@RSOS150143C8]\].

2.. Method {#s2}
==========

Let us briefly introduce the technique and the descriptors which were then applied to the genomic data. For {*X*~1~,*X*~2~,...,*X*~*n*~}*n* independent real-valued variables ordered in increasing manner *X*~1~≤*X*~2~≤⋯≤*X*~*n*~, the *cumulative distribution function* (CDF) is defined as *F*(*x*)=*P*{*X*≤*x*}\[[@RSOS150143C1]--[@RSOS150143C3]\].

The *empirical distribution function* *F*~*n*~(*x*) will be $$F_{n}(x) = \left\{ \begin{matrix}
{0,} & {x < X_{1};} \\
{\frac{k}{n},} & {X_{k} \leq x < X_{k + 1},\quad k = 1,2,\ldots,n - 1;} \\
{1,} & {X_{n} \leq x.} \\
\end{matrix} \right.$$

Then the stochasticity parameter is defined as $$\lambda_{n} = \sqrt{n}\sup\limits_{x}|F_{n}(x) - F(x)|.$$Kolmogorov's theorem \[[@RSOS150143C1]\] states that for any continuous CDF *F* the following limit is converged uniformly: $$\lim\limits_{n\rightarrow\infty}P\{\lambda_{n} \leq \lambda\} = \mathit{\Phi}(\lambda),$$where the *Φ*(0)=0, $$\mathit{\Phi}(\lambda) = \sum\limits_{k = - \infty}^{+ \infty}{( - 1)}^{k}\, e^{- 2k^{2}\lambda^{2}},\quad\lambda > 0,$$and the distribution (Kolmogorov's) *Φ* is independent of *F*. For small values of λ the following approximation yields: $$\mathit{\Phi}(\lambda) \approx \frac{\sqrt{2\pi}}{\lambda}\, e^{- \pi^{2}/{8\lambda^{2}}}.$$

This method thus provides the measure of the degree of randomness (stochasticity) for sequences of *n* values within the interval of λ~*n*~ \[0.3, 2.4\] (\[[@RSOS150143C2],[@RSOS150143C3]\], see also \[[@RSOS150143C9]\]).

3.. Data {#s3}
========

The following data have been used for the analysis. Gliomas are the most frequent malignant tumours of the central nervous system and are defined by WHO grade I to grade IV classification standards and histopathological features \[[@RSOS150143C10],[@RSOS150143C11]\]. Application of novel techniques to elucidate the fundamental genetic mutations in grade II--III astroctyomas and grade IV glioblastomas is a critical next step in glioma research. Here, we interrogated exome data of 30 brain tumour patients from the Preston Robert Tisch Brain Tumor Center at Duke University as described previously \[[@RSOS150143C12]\]. The exomes of 30 patients were selected as they provided a large enough dataset to conduct our initial analysis. Each case contained four datasets corresponding to aligned paired end sequencing data files (both a forward and reverse file for each patient's tumour and normal blood). Included in this study were 15 grade III astrocytomas and 15 grade IV glioblastomas. Samples on average yielded 36 and 32 somatic mutations for grade III astrocytoma and grade IV glioblastoma, respectively. Of particular interest to the general cancer community is the prevalence of highly recurrent mutations across all types of cancer. To this end, a list of highly recurrent mutations occurring in 23 genes commonly seen in cancer was used to interrogate the dataset ([table 1](#RSOS150143TB1){ref-type="table"}). The selected genes are from a list of genes frequently mutated in cancer provided by Personal Genome Diagnostics (Baltimore, MD, USA). Next, we surveyed the exome data to identify any occurrence of these 407 highly recurrent mutations located within these 23 commonly mutated genes \[[@RSOS150143C13]\]. Table 1.Twenty-three genes commonly mutated in cancer.gene symbolgene descriptiontranscript accessionABL1c-abl oncogene 1; non-receptor tyrosine kinaseX16416AKT1v-akt murine thymoma viral oncogene homologue 1ENST00000349310AKT2v-akt murine thymoma viral oncogene homologue 2NM 001626.3ALKanaplastic lymphoma receptor tyrosine kinaseNM 004304BRAFv-raf murine sarcoma viral oncogene homologue B1NM 004333CDK4cyclin-dependent kinase 4NM 000075.2EGFRepidermal growth factor receptorNM 005228ERBB2v-erb-b2 erythroblastic leukaemia viral oncogene homologue 2NM 004448FGFR1fibroblast growth factor receptor 1NM 023110FGFR3fibroblast growth factor receptor 3NM 000142FLT3fms-related tyrosine kinase 3NM 004119HRASv-Ha-ras Harvey rat sarcoma viral oncogene homologueNM 005343IDH1isocitrate dehydrogenase 1 (NADP+); solubleNM 005896.2IDH2isocitrate dehydrogenase 2 (NADP+); mitochondrialNM 002168.2JAK2Janus kinase 2ENST00000381652KITv-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homologueNM 000222KRASv-Ki-ras2 Kirsten rat sarcoma viral oncogene homologNM 004985METmet proto-oncogene (hepatocyte growth factor receptor)NM 000245METmet proto-oncogene (hepatocyte growth factor receptor)NM 001127500NRASneuroblastoma RAS viral (v-ras) oncogene homologueNM 002524PDGFRaplatelet-derived growth factor receptor; alpha polypeptideNM 006206PIK3CAphosphoinositide-3-kinase; catalytic; alpha polypeptideNM 006218.1RETret proto-oncogeneNM 020975

4.. Analysis {#s4}
============

The data for 30 patients have been analysed in the following manner. First, for each dataset the cumulative distribution function was obtained for three combinations of nucleotides (guanine, adenine, thymine and cytosine (G,A,T,C), i.e. of codons. For comparison, in one- and two-based analyses of the same data, no CDF was possible to define due to large scatter in the frequency counts; however, it was possible for the three-base empirical distribution for each particular genomic sequence, followed by obtaining of the stochasticity parameter and then Kolmogorov's function *Φ*. The fact that *Φ* was possible to define only for three-base CDF can be considered as a genuine feature linked to the nature of the genetic coding (first noted by cosmologist George Gamow in the 1950s) determined by the chemical properties of the molecules forming the nucleotides.

The above-described exome data were represented in a format of over 50 million rows, of 100-base each, i.e. in total about 10^9^-valued sequences. We analysed such datasets for 30 patients; a block of four datasets, representing paired-end sequencing, was available for each patient, including those for blood and tumour, denoted as normal and with tumour, respectively. The following aim was inquired into: whether the Kolmogorov--Arnold (K--A) technique is able to distinguish the strings, i.e. sequence pieces of given length, with and without mutations, for a given sample of mutations. [Figure 1](#RSOS150143F1){ref-type="fig"} represents the results for computations for 100-base rows containing such mutations in all 119 blocks (dark column on the right; one file was corrupted), and the mean of the function *Φ* for 50 rows without mutations (light-coloured column on the left) in the same sequence where the former mutations have been located. The same procedure has been repeated for shorter, i.e. for 50 and 25-base strings with and without mutations (the right two double-columns, respectively). The shorter, 50-base strings were generated in the following manner: if the mutation is located completely either in the first or the second half of the 100-base string, then the corresponding halves were included in the analysis. In the case of partial location, the proper number of bases was included from either side, that is the mutations are included completely even at part passage to the next row. The case for 25-base strings was similar, while for no-mutation strings (rows) their initial 50 or 25-base parts were included in the analysis. For no-mutation rows their alignment, i.e. their position in the sequence, was not important. The error bars correspond to standard errors. The analysis was performed by means of a software created in *Pascal* in environment *Delphi* and intended to be made public in due course. The CPU time for one sequence (about 10^9^ nucleotides) is about 1 h for an i7, 2600 3.4 GHz processor of 6 GB memory. Figure 1.The function *Φ* averaged for rows with mutations (dark bars) and normal ones (light bars) averaged over 50 rows, for 100, 50 and 25-base rows (here denoted as word), correspondingly. Error bars correspond to standard errors.

Then, rows containing the most frequent specific mutations in the same dataset of 30 patients ([table 2](#RSOS150143TB2){ref-type="table"}) were analysed. Obviously, more frequent mutations provide higher statistics, and [table 2](#RSOS150143TB2){ref-type="table"} and [figure 2](#RSOS150143F2){ref-type="fig"} are represented to show the scales of the input frequency numbers versus the results. The mutations, i.e. the genes, the mutant positions and amino acid changes, are known for the codes listed in [table 2](#RSOS150143TB2){ref-type="table"}, and from the individual mutation reports of the performed studies \[[@RSOS150143C12]\] one can list all mutations contained within each tumour; we intend to address these issues in further publications on the applications of the method discussed here. The results for the mean *Φ* with standard error bars are presented in [figure 2](#RSOS150143F2){ref-type="fig"}. One can see that certain specific mutations can be distinguished by the value of mean *Φ*. Figure 2.The same as in [figure 1](#RSOS150143F1){ref-type="fig"}, but with the averaged values of the function *Φ* for 100-base rows for the highest recurrent specific mutations in the studied dataset as listed in [table 2](#RSOS150143TB2){ref-type="table"}. Table 2.The codes (MC) and frequency counts for seven highest recurrent mutations in the studied database.NMCfrequency`1``AAAGANAAATT``3032``2``CATCTNAAAAA``2569``3``AGAAGNAAAAA``2427``4``ATTTTNTCTTT``2409``5``TGCCCNGGCTG``2253``6``CTTTCNTTTCT``2200``7``TCTTCNTTTTT``2123`

5.. One step further: possibility for discovering new mutations {#s5}
===============================================================

Up to now we were estimating the Kolmogorov function *Φ* for genomic sequence pieces (rows) with known mutations and without (those) mutations. We reveal the differences in the mean values of *Φ* for rows with and without those mutations. If so, then one can pose the inverse problem, namely, one can try to detect unknown mutations based on the value of *Φ*, if estimated blindly in a given genome sequence. In [table 3](#RSOS150143TB3){ref-type="table"}, we show the results for a sample from the above studied database from genome with tumour (081T1): 11 rows (of over 50 million) with *Φ*\>0.7 (only the rows with the number of unidentified nucleotides *n*≤3 have been taken into account) have been revealed with the codes given in [table 3](#RSOS150143TB3){ref-type="table"} as candidates for mutations. Obviously, certain parts of these cases can be just noise, i.e. without any association with real mutations; however, if at least part of this list when studied by conventional methods can be confirmed as associated with mutations, then one will have an explicit tool for detection of unknown mutations by means of this relatively simple (i.e. consuming little time and manpower) method. Certainly, the exhaustive answer to this question will need comprehensive parallel studies with different analysis methods. However, for now, for illustration, for the given sample of detected candidates for mutations, we performed the following. We sampled five reads from the aforementioned list of 11 rows in [table 3](#RSOS150143TB3){ref-type="table"} and aligned them to the human genome for further investigation. While none of these five reads matched to previously reported mutations in the COSMIC database, one of the reads aligned to a region of interest to oncogenomic laboratories. This read aligned to the transcriptional regulator ARID1A, an SWI/SNF family member that is frequently mutated in numerous types of cancers, including gastric, ovarian and pancreatic cancers \[[@RSOS150143C14]--[@RSOS150143C17]\]. Probability for a chance coincidence is less than 10^−5^ (assuming for simplicity an equipartition in the frequency counts, cf. [table 2](#RSOS150143TB2){ref-type="table"}), thus proving the efficiency of the method for blind application to datasets using the previously calibrated *Φ*. Table 3.The codes for candidates for mutations in a genome sequence with high *Φ* at given row numbers.line NMC`1186009``TTGTGNAAGGG``4073568``CCACGNCCTGG``11648505``ATACANAACGC``21240249``AAGGANACTGA``21827969``CAATTNGGGAA``33372865``GCCGGNCGCGG``34549019``TGGCCNAGAAG``36995074``TGAAGNGTTCT``42622891``TTGTTNTTTTA``43978737``AGAAANATATT``50647272``TGACTNAAAGG`

Another potential application for this technique involves detection of rare variants of sequencing data, where the parameter *Φ* may recognize genomic sequences that are in extremely low abundance and warrant further investigation by the researchers.

6.. Conclusion {#s6}
==============

The following basic conclusions can be drawn from the above analysis:

(i) the stability of the descriptor, that is small standard errors and hence high and stable confidence levels of the values of *Φ* for paired-end sequence rows both for normal, i.e. without mutations, and those with mutations;(ii) the difference in values of *Φ* for rows with and without mutations;(iii) the considered variations of string lengths still reflect the tendency; and(iv) rows with certain mutations can be distinguished by means of the used marker.

The presented results demonstrate for the greater cancer research community the power of the K--A technique for identification of mutations in paired-end genome sequencing data. In addition to the significance of revealing the important nature of the difference in the degree of the randomness between the genome sequence with and without mutations, the method also has an important application potential. It may be applied to non-aligned sequencing segments, which may significantly simplify the procedure of finding segments with mutations and could speed up genomic research and its implementation in clinical diagnostics (cf. \[[@RSOS150143C18]--[@RSOS150143C20]\]).

Finally, the consideration of the inverse problem, namely, the revealing of a mutation associated with a tumour based purely on the computation of the value of the marker when blinded to the data, indicates that the latter may be used for detection of rare or new types of mutations.
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